CJC-1295 with or without DAC?

CJC-1295 with DAC (Drug Affinity Complex) has a 5-8 day half-life thanks to its binding to serum albumin — practical for injections 2× per week. CJC-1295 without DAC (or 'modified GRF 1-29') has a half-life of only a few minutes and requires frequent injections 2-3× per day. For standard practice, version with DAC more accessible and simpler. Version without DAC sometimes preferred by purists to mimic physiological pulses.

Ipamorelin or GHRP-6?

Ipamorelin, for selectivity. GHRP-6 has a more marked ghrelin effect (increased appetite) and can modestly raise cortisol and prolactin at high doses, while ipamorelin is selective for the pituitary GHSR1a receptor without counter-regulatory effects. Much better tolerance profile under ipamorelin for long cycles. GHRP-6 retains its interest if the orexigenic effect is sought (in users in caloric surplus struggling to eat).

Side effects of GH-axis peptides?

Overall well tolerated. Extremity numbness (tissue fluid retention), sometimes transient carpal tunnel syndrome at high doses. Possible slight insulin resistance (fasting glycemia +5-10 mg/dL on long cycle), reversible on cessation. No hormonal suppression (no action on HPG axis), no aromatization. Low theoretical oncologic risk with modest IGF-1 elevation (vs exogenous HGH where IGF-1 can double).

CJC + ipamorelin combo vs exogenous HGH?

HGH more potent in IGF-1 elevation (+100-300% per dose) but more expensive (200-500 €/month) and more risky (acromegaly, insulin resistance, non-selective tissue growth). Peptide combo more physiological: amplifies endogenous pulses (preserves natural pulsatility), IGF-1 elevation +50-100% sufficient for modest anabolic effect, lower cost (~50-100 €/month). For user aiming at reasonable GH-axis effect without HGH budget, peptide combo is largely preferable.

When to inject GH-axis peptides?

Ipamorelin: 2-3× per day at strategic moments — morning fasting (morning natural GH peak), post-workout (anabolic window), before bed (favors nocturnal GH peak and deep sleep quality). Always SC, ideally fasting (plasma amino acids and carbohydrates partially inhibit the GH pulse triggered by GHRP). CJC-1295 DAC: timing less critical thanks to long half-life, 2× per week SC at regular times (e.g., Monday/Thursday).

IGF-1 effect expected under peptide combo?

+50-100% vs baseline in monitoring mid-cycle (W6-W8). For user whose baseline IGF-1 is at 200 ng/mL, expect 300-400 ng/mL under CJC + ipamorelin × 12 weeks. If no elevation at W6, doses probably underdosed or product not authentic. Serum IGF-1 panel before and mid-cycle to calibrate. If IGF-1 > 500 ng/mL, lower doses to limit acromegaly-like risk.

How long to use these peptides?

Typical 12-week cycle then 4-8 week break before new cycle. No PCT required (no action on HPG axis). Break useful to allow tissue sensitivity to recover and avoid GHRH/GHSR receptor desensitization. For continuous use (TRT-GH style), requires medical follow-up with IGF-1 monitoring, glycemia, and regular tissue panel (cardiac echography, abdominal).

CJC + ipamorelin in seniors or anti-aging?

Widespread use in American anti-aging clinics (functional medicine, longevity). Rationale: endogenous GH secretion declines progressively after 30-40 years (somatopause), and the CJC + ipamorelin combo modestly restores GH/IGF-1 levels to those of a young adult. Felt effects: improved deep sleep quality, faster muscular and tendinous recovery, more toned skin, visceral lipolysis (metabolic effect). Not an official medication but frequent off-label use in integrative medicine.

CJC-1295 vs Ipamorelin: complete comparison (GHRH vs GHRP, GH axis)

Critère	cjc-1295	ipamorelin
Class	GHRH analog	GHRP (ghrelin-like peptide)
Mechanism	GH pulse amplitude	GH pulse frequency
Half-life	~5-8 d (CJC-1295 DAC)	~2 h
Cortisol effect	None	None (selective vs GHRP-6)
Prolactin effect	None	None
Appetite effect (ghrelin)	None	Modest
Typical dose	1-2 mg 2× per week	200-300 µg 2-3× per day
Route	SC	SC

Quand choisir cjc-1295

CJC-1295 is a stabilized analog of GHRH (Growth Hormone Releasing Hormone), designed to amplify endogenous GH secretion by the pituitary. Teichman 2006 (phase 1 study in humans) demonstrated sustained GH and IGF-1 elevation at 0.5-2 mg, with effect maintained for several days thanks to the DAC version (Drug Affinity Complex) which binds to serum albumin and prolongs half-life to 5-8 days. Choose it for: (1) a GH-axis cycle with spaced dosing (2 injections per week), (2) a sustained and smooth anabolic effect on the GH/IGF-1 axis, (3) a complement to an AAS cycle to support recovery and body composition, (4) a user preferring few injections. Pharmacological profile (Sigalos 2018, Bowers 1984 on the GHRH class): amplifies amplitude of natural GH pulses without modifying their frequency, no cortisol effect, no prolactin effect, acceptable safety in short cycle. Drawbacks: modest effect alone (GH pulses depend on pulsed endogenous secretion — without GHRP in parallel, CJC alone does not trigger pulses, it amplifies those that exist), no long-term human studies, underground market with variable purity. Typical dose 1-2 mg 2× per week SC × 12 weeks. IGF-1 effect +20-40% in monotherapy, +50-80% in combo with GHRP.

Quand choisir ipamorelin

Ipamorelin is a selective GHRP (Growth Hormone Releasing Peptide) synthesized in 1998 by Novo Nordisk (Raun 1998). Choose it for: (1) a GH-axis effect without counter-effects (cortisol elevation, prolactin, appetite) specific to older GHRPs (GHRP-6, GHRP-2), (2) triggering endogenous GH pulses several times per day, (3) a complement to an AAS cycle or CJC-1295 to support the GH/IGF-1 axis. Pharmacological profile (Sigalos 2018, Kojima 1999 on the ghrelin-like class): activation of GHSR1a receptor (ghrelin) on the pituitary → triggering an endogenous GH pulse, short half-life (~2 h) requiring multiple injections per day for sustained effect. Specific ipamorelin vs GHRP-6 advantages: no cortisol elevation (no adrenal fatigue on long cycle), no prolactin elevation (no progestogenic gynecomastia risk), low appetite (vs GHRP-6 which strongly increases appetite). Drawbacks: frequent injections (2-3× per day), more subtle effect than 'raw' GHRPs, no long-term data. Typical dose 200-300 µg 2-3× per day SC × 12 weeks.

Combinaison ?

The CJC-1295 + ipamorelin combo is the standard of GH-axis stimulation in bodybuilding practice: CJC-1295 1-2 mg 2× per week + ipamorelin 200-300 µg 2-3× per day (morning fasting, immediate post-workout, and before bed) × 12 weeks. Pharmacological synergy (Sigalos 2018): CJC-1295 amplifies amplitude of endogenous GH pulses (classic GHRH effect), ipamorelin triggers additional pulses via the GHSR1a receptor (GHRP effect) — the result is a sustained and physiological GH and IGF-1 elevation (+50-100% vs baseline per dose and duration). Specific advantages: no cortisol/prolactin/appetite side effects (unlike GHRP-6 or GHRP-2 mixed with CJC), favorable tolerance profile even in long cycle, economical and more physiological alternative to exogenous HGH (which raises IGF-1 to non-physiological levels and costs 5-10× more). Biological monitoring: serum IGF-1 at W0, W6, W12 to calibrate doses (if IGF-1 exceeds 500 ng/mL, lower doses); fasting glycemia and HbA1c (GH-axis compounds can modestly alter insulin sensitivity on long cycle, +5-10 mg/dL). Subjective monitoring: extremity numbness (tissue fluid retention, transient carpal tunnel syndrome), deep sleep quality (often reported improvement), muscular and tendinous recovery. Sample 12-week GH-axis timeline: W0 baseline IGF-1 + glycemia + HbA1c + lipids + sleep quality assessment, W1 start, W2 first sleep and appetite subjective assessment, W4 IGF-1 recheck (should be rising +30-50%), W6 mid-cycle full panel including glycemia, W8 IGF-1 + lipids, W10 final assessment, W12 stop both compounds, W16 follow-up panel and 4-8 week off before next cycle. Practical injection scheduling: ipamorelin morning fasted + post-workout + bedtime maximizes 24-hour GH pulse coverage; CJC-1295 DAC every Monday and Thursday for steady-state albumin binding. Subjective sleep quality improvement is the fastest noticeable effect (week 2-3). Sample baseline panel must include IGF-1 (the primary biomarker), fasting glucose and HbA1c (both compounds modestly affect insulin sensitivity), lipids, T total (no direct effect but useful for general health context), and resting BP averaged over three days. Echocardiography baseline recommended for chronic users to track any organ growth signal under sustained IGF-1 elevation.

FAQ

CJC-1295 with or without DAC?: CJC-1295 with DAC (Drug Affinity Complex) has a 5-8 day half-life thanks to its binding to serum albumin — practical for injections 2× per week. CJC-1295 without DAC (or 'modified GRF 1-29') has a half-life of only a few minutes and requires frequent injections 2-3× per day. For standard practice, version with DAC more accessible and simpler. Version without DAC sometimes preferred by purists to mimic physiological pulses.
Ipamorelin or GHRP-6?: Ipamorelin, for selectivity. GHRP-6 has a more marked ghrelin effect (increased appetite) and can modestly raise cortisol and prolactin at high doses, while ipamorelin is selective for the pituitary GHSR1a receptor without counter-regulatory effects. Much better tolerance profile under ipamorelin for long cycles. GHRP-6 retains its interest if the orexigenic effect is sought (in users in caloric surplus struggling to eat).
Side effects of GH-axis peptides?: Overall well tolerated. Extremity numbness (tissue fluid retention), sometimes transient carpal tunnel syndrome at high doses. Possible slight insulin resistance (fasting glycemia +5-10 mg/dL on long cycle), reversible on cessation. No hormonal suppression (no action on HPG axis), no aromatization. Low theoretical oncologic risk with modest IGF-1 elevation (vs exogenous HGH where IGF-1 can double).
CJC + ipamorelin combo vs exogenous HGH?: HGH more potent in IGF-1 elevation (+100-300% per dose) but more expensive (200-500 €/month) and more risky (acromegaly, insulin resistance, non-selective tissue growth). Peptide combo more physiological: amplifies endogenous pulses (preserves natural pulsatility), IGF-1 elevation +50-100% sufficient for modest anabolic effect, lower cost (~50-100 €/month). For user aiming at reasonable GH-axis effect without HGH budget, peptide combo is largely preferable.
When to inject GH-axis peptides?: Ipamorelin: 2-3× per day at strategic moments — morning fasting (morning natural GH peak), post-workout (anabolic window), before bed (favors nocturnal GH peak and deep sleep quality). Always SC, ideally fasting (plasma amino acids and carbohydrates partially inhibit the GH pulse triggered by GHRP). CJC-1295 DAC: timing less critical thanks to long half-life, 2× per week SC at regular times (e.g., Monday/Thursday).
IGF-1 effect expected under peptide combo?: +50-100% vs baseline in monitoring mid-cycle (W6-W8). For user whose baseline IGF-1 is at 200 ng/mL, expect 300-400 ng/mL under CJC + ipamorelin × 12 weeks. If no elevation at W6, doses probably underdosed or product not authentic. Serum IGF-1 panel before and mid-cycle to calibrate. If IGF-1 > 500 ng/mL, lower doses to limit acromegaly-like risk.
How long to use these peptides?: Typical 12-week cycle then 4-8 week break before new cycle. No PCT required (no action on HPG axis). Break useful to allow tissue sensitivity to recover and avoid GHRH/GHSR receptor desensitization. For continuous use (TRT-GH style), requires medical follow-up with IGF-1 monitoring, glycemia, and regular tissue panel (cardiac echography, abdominal).
CJC + ipamorelin in seniors or anti-aging?: Widespread use in American anti-aging clinics (functional medicine, longevity). Rationale: endogenous GH secretion declines progressively after 30-40 years (somatopause), and the CJC + ipamorelin combo modestly restores GH/IGF-1 levels to those of a young adult. Felt effects: improved deep sleep quality, faster muscular and tendinous recovery, more toned skin, visceral lipolysis (metabolic effect). Not an official medication but frequent off-label use in integrative medicine.

CJC-1295 vs Ipamorelin: complete comparison (GHRH vs GHRP, GH axis)

Critère	cjc-1295	ipamorelin
Class	GHRH analog	GHRP (ghrelin-like peptide)
Mechanism	GH pulse amplitude	GH pulse frequency
Half-life	~5-8 d (CJC-1295 DAC)	~2 h
Cortisol effect	None	None (selective vs GHRP-6)
Prolactin effect	None	None
Appetite effect (ghrelin)	None	Modest
Typical dose	1-2 mg 2× per week	200-300 µg 2-3× per day
Route	SC	SC

Quand choisir cjc-1295

Quand choisir ipamorelin

Combinaison ?

FAQ

CJC-1295 with or without DAC?: CJC-1295 with DAC (Drug Affinity Complex) has a 5-8 day half-life thanks to its binding to serum albumin — practical for injections 2× per week. CJC-1295 without DAC (or 'modified GRF 1-29') has a half-life of only a few minutes and requires frequent injections 2-3× per day. For standard practice, version with DAC more accessible and simpler. Version without DAC sometimes preferred by purists to mimic physiological pulses.
Ipamorelin or GHRP-6?: Ipamorelin, for selectivity. GHRP-6 has a more marked ghrelin effect (increased appetite) and can modestly raise cortisol and prolactin at high doses, while ipamorelin is selective for the pituitary GHSR1a receptor without counter-regulatory effects. Much better tolerance profile under ipamorelin for long cycles. GHRP-6 retains its interest if the orexigenic effect is sought (in users in caloric surplus struggling to eat).
Side effects of GH-axis peptides?: Overall well tolerated. Extremity numbness (tissue fluid retention), sometimes transient carpal tunnel syndrome at high doses. Possible slight insulin resistance (fasting glycemia +5-10 mg/dL on long cycle), reversible on cessation. No hormonal suppression (no action on HPG axis), no aromatization. Low theoretical oncologic risk with modest IGF-1 elevation (vs exogenous HGH where IGF-1 can double).
CJC + ipamorelin combo vs exogenous HGH?: HGH more potent in IGF-1 elevation (+100-300% per dose) but more expensive (200-500 €/month) and more risky (acromegaly, insulin resistance, non-selective tissue growth). Peptide combo more physiological: amplifies endogenous pulses (preserves natural pulsatility), IGF-1 elevation +50-100% sufficient for modest anabolic effect, lower cost (~50-100 €/month). For user aiming at reasonable GH-axis effect without HGH budget, peptide combo is largely preferable.
When to inject GH-axis peptides?: Ipamorelin: 2-3× per day at strategic moments — morning fasting (morning natural GH peak), post-workout (anabolic window), before bed (favors nocturnal GH peak and deep sleep quality). Always SC, ideally fasting (plasma amino acids and carbohydrates partially inhibit the GH pulse triggered by GHRP). CJC-1295 DAC: timing less critical thanks to long half-life, 2× per week SC at regular times (e.g., Monday/Thursday).
IGF-1 effect expected under peptide combo?: +50-100% vs baseline in monitoring mid-cycle (W6-W8). For user whose baseline IGF-1 is at 200 ng/mL, expect 300-400 ng/mL under CJC + ipamorelin × 12 weeks. If no elevation at W6, doses probably underdosed or product not authentic. Serum IGF-1 panel before and mid-cycle to calibrate. If IGF-1 > 500 ng/mL, lower doses to limit acromegaly-like risk.
How long to use these peptides?: Typical 12-week cycle then 4-8 week break before new cycle. No PCT required (no action on HPG axis). Break useful to allow tissue sensitivity to recover and avoid GHRH/GHSR receptor desensitization. For continuous use (TRT-GH style), requires medical follow-up with IGF-1 monitoring, glycemia, and regular tissue panel (cardiac echography, abdominal).
CJC + ipamorelin in seniors or anti-aging?: Widespread use in American anti-aging clinics (functional medicine, longevity). Rationale: endogenous GH secretion declines progressively after 30-40 years (somatopause), and the CJC + ipamorelin combo modestly restores GH/IGF-1 levels to those of a young adult. Felt effects: improved deep sleep quality, faster muscular and tendinous recovery, more toned skin, visceral lipolysis (metabolic effect). Not an official medication but frequent off-label use in integrative medicine.